MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
60.09
-0.16 (-0.27%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close60.25
Open60.41
Bid59.36 x 800
Ask60.75 x 600
Day's Range59.77 - 61.00
52 Week Range52.83 - 66.41
Volume13,334,877
Avg. Volume12,770,116
Market Cap161.805B
Beta1.11
PE Ratio (TTM)69.07
EPS (TTM)0.87
Earnings DateMay 1, 2018
Forward Dividend & Yield1.92 (3.38%)
Ex-Dividend Date2018-03-14
1y Target Est68.40
Trade prices are not sourced from all markets
  • Gilead Sciences Focuses on Its Liver Disease Portfolio
    Market Realist12 hours ago

    Gilead Sciences Focuses on Its Liver Disease Portfolio

    By mid-2018, Gilead Sciences (GILD) expects its share of the HCV (hepatitis C) market, where it competes with AbbVie (ABBV), Merck (MRK), and Bristol-Myers Squibb (BMY), to stabilize. This stabilization is anticipated despite rapidly declining drug prices and reducing treatment duration due to new and better therapies. While the company is not expecting any disruptive product launches in the HCV segment in the next few years, it expects gradually declining patient numbers to affect revenue. Liver disease research programs

  • How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18
    Market Realist19 hours ago

    How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18

    About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.

  • Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma
    Motley Fool21 hours ago

    Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma

    It's a lot easier to be patient once those quarterly payments start adding up.

  • Henry Schein to Merge Animal Health with Vets First Choice
    Market Realist21 hours ago

    Henry Schein to Merge Animal Health with Vets First Choice

    On April 23, Henry Schein (HSIC) announced its plans to spin off and merge its animal health business with Vets First Choice to form a joint venture, Vets First Corp., aimed to advance animal healthcare and benefit veterinarians, pets, product manufacturers, and pet owners. Henry Schein, one of the world’s largest global supply chain providers of animal health products, has established a top market position in North America, Europe, Australia, and New Zealand.

  • InvestorPlace21 hours ago

    The Treasury Yield Is Trembling on the Edge of 3%

    U.S. equities finished near the unchanged line on Monday as investors braced for the beginning of a very busy week of earnings reports. And much attention is being paid in the rise in long-term interest rates, with the 10-year Treasury yield within millimeters of crossing the 3% threshold (2.998%).

  • Investopedia23 hours ago

    Merck Shares Seen Rising 12% as Profits Jump

    Merck & Co. Inc.'s ( MRK) stock has had a rough three years with shares rising by a little more than 4%, versus an S&P 500 that has climbed by nearly 27%. The average price target on the stock is $67.68, nearly 12% higher than the stock's current price around $60.30. The chart shows a solid uptrend that has been in place for Merck since 2009—a decade-long uptrend.

  • Reutersyesterday

    AstraZeneca flop a fresh blow to cancer immunotherapy combination

    The concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an AstraZeneca clinical study. Adding the company's experimental drug tremelimumab to its existing product Imfinzi failed to slow disease progression or extend life in patients who had already received at least two previous treatments, the drugmaker said on Tuesday.

  • Investopediayesterday

    AstraZeneca’s Lung Cancer Duo Flops

    AstraZeneca’s combo of the experimental drug tremelimumab and Imfinzi failed to slow disease progression or extend life for lung cancer patients

  • Business Wire2 days ago

    European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic Nonsquamous NSCLC, Based on Phase 3 KEYNOTE-189 Trial

    Merck , known as MSD outside the United States and Canada, today announced that following validation by the European Medicines Agency , the centralized review process has begun for the company’s Type II Variation, which seeks approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous ...

  • MarketWatch2 days ago

    Merck's stock surges to lead Dow's gainers after Goldman turns bullish

    Shares of Merck & Co. Inc. ran up $1.61, or 2.7%, to a near three-month high in afternoon trade Monday, enough to pace the Dow Jones Industrial Average's gainers, after Goldman Sachs turned bullish on ...

  • Benzinga2 days ago

    Keytruda Is Key To The Merck Thesis, Goldman Sachs Says In Upgrade

    The Merck & Co., Inc. (NYSE: MRK ) story has slowly captivated analysts, and on Monday the pharmaceutical company corralled Goldman Sachs in its growing bullpen.  The Rating Analyst Jami Rubin upgraded ...

  • Reuters2 days ago

    P&G to buy German Merck's consumer health unit for $4.2 billion

    The maker of Pampers diapers and Gillette razors said the deal would help it expand its portfolio of consumer healthcare products which includes Vicks cold relief. The Merck unit includes vitamin brands Femibion and Neurobion. The deal follows GlaxoSmithKline agreeing to buy Novartis out of their consumer healthcare joint venture for $13 billion after dropping its pursuit of Pfizer's consumer unit.

  • Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
    Market Realist2 days ago

    Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall

    As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.

  • Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
    Market Realist2 days ago

    Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

    Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.

  • What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings
    Market Realist2 days ago

    What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings

    GlaxoSmithKline (GSK) is set to release its 1Q18 earnings on April 25, 2018. The below chart shows the company’s revenues and earnings per share (or EPS) since 1Q17 and analysts’ estimates for 1Q18. Analysts estimate the company will post EPS of 24.21 pence on revenues of 7.2 billion pounds in 1Q18.

  • Reuters5 days ago

    U.S. biotech companies Alnylam, Dicerna settle trade secrets case

    Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments. The settlement between the two biotech companies resolves a lawsuit that Alnylam filed against Dicerna in 2015. Under the agreement, Dicerna said it will pay Alnylam $2 million up-front plus 983,208 shares of its common stock.

  • Germany's Merck seeks partners for cancer and immune system drugs
    Reuters5 days ago

    Germany's Merck seeks partners for cancer and immune system drugs

    Merck KGaA will seek development partners for experimental treatments including tepotinib as the German company looks to licensing deals to help fund clinical trials, according to its head of drug R&D. Merck has a promising drug pipeline for the first time in several years. It is looking to take a collaborative approach, as an expected decline in operating profit this year forces it to find new ways to finance pharmaceutical development.

  • What's in the Cards for Glaxo (GSK) This Earnings Season?
    Zacks5 days ago

    What's in the Cards for Glaxo (GSK) This Earnings Season?

    Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.

  • Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
    Zacks5 days ago

    Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

    Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

  • J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
    Zacks5 days ago

    J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?

    Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.

  • TheStreet.com5 days ago

    Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business

    Procter & Gamble, which is buying the Merck unit, was previously reported to be in talks to acquire Pfizer's consumer healthcare business.

  • The Wall Street Journal5 days ago

    Corrections & Amplifications

    Merck KGaA’s products include Femibion, a supplement for women. A Business News article in some editions Thursday about the sale of Merck KGaA’s consumer-health unit to Procter & Gamble Co. incorrectly ...

  • P&G to buy German Merck's consumer health unit for $4.2 billion
    Reuters5 days ago

    P&G to buy German Merck's consumer health unit for $4.2 billion

    The maker of Pampers diapers and Gillette razors said the deal would help it expand its portfolio of consumer healthcare products which includes Vicks cold relief. The Merck unit includes vitamin brands Femibion and Neurobion. The deal follows GlaxoSmithKline (GSK.L) agreeing to buy Novartis (NOVN.S) out of their consumer healthcare joint venture for $13 billion after dropping its pursuit of Pfizer's (PFE.N) consumer unit.